Merck & Company, Inc. vs Intellia Therapeutics, Inc. — Stock Comparison
Q·Score Breakdown
6.7
Neutral
Overall
6.2
Neutral
Quality
Health
Growth
Valuation
Sentiment
MRK
Forward P/E of 11.5× is low relative to sector peers.
NTLA
Clean balance sheet with low leverage (0.1× debt-to-equity).
⚠ low return on equity (-53%).
Analyst Consensus
BUY
Target $129.74 (+15.7%)
27 analysts
BUY
Target $26.71 (+101.5%)
21 analysts
Fundamentals
MRK
NTLA
31.5×
Trailing P/E
—
11.5×
Forward P/E
-4.6×
13.6%
Profit Margin
0.0%
76.6%
Gross Margin
0.0%
—
ROE
-53.5%
4.9%
Revenue Growth
78.8%
—
Earnings Growth
—
0.28
Beta
1.99
—
Price / Book
—
$277.0B
Market Cap
$1.6B
$73 – $125
52-Week Range
$7 – $28
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →